BiotechTube

177Lu-FAP-2286

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cancer of Unknown Primary

Conditions

Cancer of Unknown Primary

Trial Timeline

Jun 1, 2026 → Jun 1, 2030

NCT ID
NCT07434180

About 177Lu-FAP-2286

177Lu-FAP-2286 is a phase 2 stage product being developed by Novartis for Cancer of Unknown Primary. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07434180. Target conditions include Cancer of Unknown Primary.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT07434180Phase 2Recruiting

Competing Products

20 competing products in Cancer of Unknown Primary

See all competitors
ProductCompanyStageHype Score
E7389EisaiPhase 1
33
VeliparibAbbViePhase 2
52
AK-105AkesoPhase 1
32
XL820ExelixisPhase 1
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
LymphoseekNavidea BiopharmaceuticalsPhase 3
69
ALT-P7 (HM2-MMAE)AlteogenPhase 1
33
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
23
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
52
pemetrexedEli LillyPhase 2
52
LY3300054 + PrexasertibEli LillyPhase 1
33
BBP-398 with nivolumabBridgeBio PharmaPhase 1
30
Cetuximab + Oxaliplatin + CapecitabineEli LillyPhase 2
52
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
52
SelpercatinibEli LillyPre-clinical
23
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
77
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRTNanobiotixPhase 1/2
36
NBTXR3NanobiotixPhase 1/2
36

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85